Eric Forsberg Email & Phone Number

Boston, Ma, Us

Cambridge, Massachusetts, Us

Durham, Nc, Us

Provided strategic and managerial oversight of bioanalytical method development, validation, and sample testing of ligand binding assays (biomarker, PK, immunogenicity) supporting small and large molecule therapeutics under GLP/GCLP. Provided clients with quality and on-time delivery of contracted services. Bioanalytical project management.

Hampton, Nj, Us

Managed a team of five scientists in the clinical and preclinical groups, while coordinating efforts from R&D groups in MA, CT, and NJ locations to achieve department goals. Designed, planned, conducted, and monitored studies using ELISA/ECL-based PK, ADA, and biomarker assays to support drug development of antibody biologics (monoclonals and bispecifics). Reviewed raw data for accuracy, completeness, and compliance with industry best practices for bioanalytical assay development and validation.

Hampton, Nj, Us

Managed a team conducting the development and validation of new LBAs to assess the PK and ADA of our immunotherapy pipeline for IND-enabling toxicity studies. Authored and approved technical documents, such as GLP protocols, methods, procedures, and reports. Worked closely with QA to ensure quality, consistency, and compliance with in-phase and data transfer audits. Contributed to the validation of SoftMax GXP and MSD’s Discovery Workbench software under 21 CFR Part 11.

Hampton, Nj, Us

Conducted animal studies to demonstrate proof-of-concept in several in-vivo tumor models to assess efficacy. Oversaw sample testing, conducted data analysis, and presented data to cross functional internal teams. Developed and validated several PK and ADA assays in compliance with GLP regulations and FDA guidance documents.

Hampton, Nj, Us

Partnered with Celldex science teams during the AVANT acquisition and integration of assay methods and staff. Researched and introduced new techniques while simultaneously training junior staff to maintain delivery schedules throughout the transition.

Us

Optimized dosing regimens and delivery methods of cholesterol ester transfer protein (CETP) vaccines, developed to decrease HDL blood levels, in animal models and confirmed immunogenicity via ELISA.

Us

Assessed the immunogenicity of bacterial-vector based vaccine candidates against Cholera, Typhoid Fever, Shigella, and Plague. Assessed the potency and rat pharmacokinetics of anti-inflammatory agent, TP10 (sCR1).

Boston, Massachusetts, Us

Analyzed samples from a clinical trial for an Autoantigen Vaccination in Human Type 1 Newly Diagnosed Diabetes Mellitus. Assessed levels of IL-4, IL-10, and IFN by ELISA. Conducted insulin autoantibody radio assays to determine serum antibody levels. Performed T-cell receptor spectratype analysis between healthy subjects and Type 1 diabetics.

Worcester, Ma, Us

Isolated intestinal intraepithelial lymphocytes, T cells from lymphoid organs, and pancreatic islet cells for downstream processes. Explored the variation of cell surface markers in the induction of IDDM using the BB rat model via flow cytometry. Performed enzymatic radio assays analyze the NADase activity of a regulatory RT6 T cell protein. Assessed levels of cytokines via ELISpot before, during, and after the onset of diabetes.